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Over the last 30 years, an abundance of
studies have clearly demonstrated that
2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) is extremely toxic to experimental
animals (1-3). Fish and wildlife are also
sensitive to the toxic effects ofthis chemical
(4). TCDD is carcinogenic in male and
female rats and mice, male hamsters, and
male and female fish (5,6). Reproductive
and developmental toxicity has been
observed in all experimental animals tested.
Immunotoxic effects occur in mice, rats,
and nonhuman primates exposed to low
doses ofTCDD (7). Evidence to date indi-
cates that the actions ofTCDD are mediat-
ed by the Ah receptor (8,9) which functions
as a signal transducer and transcription fac-
tor. In many ways the actions of the Ah
receptor are similar to those of the steroid
hormone receptors (10,11), although the
Ah receptor is not a member of this super-
family of proteins (12,13). Other halo-
genated dibenzo-p-dioxins and dibenzofu-
rans substituted in all four lateral positions
also have high binding affinity to the Ah
receptor and induce the same spectrum of
toxicity as TCDD (14). In addition, certain
polyhalogenated biphenyls, naphthalenes,
and diphenyl ethers are Ah receptor ago-
nists. Humans are exposed to complex mix-
tures of these chemicals; estimates of daily
exposure to TCDD or "dioxinlike" (all
2,3,7,8-halogenated dibenzo-p-dioxins and
dibenzofurans as well as the dioxinlike
polychlorinated biphenyls) chemicals is
3-6 pg TCDD equivalents/kg/day in the
United States (15,16). The subclass ofthe
polyhalogenated aromatic hydrocarbons
with dioxinlike activity are referred to as
dioxins in this article.
Although the toxic effects ofdioxins in
experimental animals are unequivocal,
their toxic effects in humans are less cer-
tain. Chloracne is the only toxic effect
induced by dioxins for which there is
unequivocal evidence linking exposure to
effect in humans (17). The uncertainty of
other toxic effects ofdioxins in humans is
due to the scarcity of human populations
with high dose exposures, limited data on
the body burdens of dioxins present in
these populations, the difficulty in assess-
ing sensitive toxic endpoints in humans,
and the lack ofknowledge about likely, but
unknown, genetic factors that may influ-
ence the relative susceptibility ofindividu-
als. Dioxins produce some ofthe same bio-
chemical alterations in humans and experi-
mental animals (18). Several recent epi-
demiological studies suggest an association
between dioxin exposure and increased
incidence of cancer (19-23) and increased
incidence of altered glucose tolerance in
exposed populations (24,25). One way to
determine the strength of an association
between dioxin exposure and a toxic effect
in humans would be to compare the dose of
dioxin that is required to produce an effect
in animals to the dose ofdioxin in humans
that is associated with a similar toxic effect.
While it is clear that for some toxic effects,
such as lethality and bodyweight loss, there
are marked species differences in suscepti-
bility to dioxins, many recent studies have
also noted that for other endpoints, such as
reproductive and developmental effects,
most animal species respond at similar
doses (9,26). Thus, the dose of dioxin that
produces a particular effect in experimental
animals might be expected to be similar to
the dose ofdioxin associated with that same
effect in humans.
Although the hypothesis that toxic doses
ofdioxins in animals and humans are simi-
lar for most responses is theoretically
testable using data from accidentally
exposed human populations, there are some
difficulties. In particular, it is often difficult
to determine the human dosage at the time
of exposure. In experimental studies, ani-
mals are administered a known amount of
dioxin and evaluated at a specific time after
the treatment. In humans the actual expo-
sure is unknown and often difficult to esti-
mate. Several epidemiological studies deter-
mined serum concentration of dioxins in
exposed and control populations (19-25).
Although the dose to the individuals in
these studies is uncertain, the body burdens
of dioxins in these populations can be esti-
mated at a specific point in time. In addi-
tion, serum and tissue dioxin concentrations
from populations in the United States with-
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out any unusually high exposures have been
reported from several different laboratories
(27-30). All humans in industrialized
countries are presumed to carry a body bur-
den of dioxins based primarily on con-
sumption ofminute quantities ofdioxin in
the food supply. Here we compare the body
burdens of dioxins that produce effects in
experimental animals to the body burdens
associated with effects in humans, based on
the clinical findings observed during epi-
demiological studies. A comparison of the
in vitro effects of dioxins on human and
animal tissues and cell cultures is also pre-
sented. This analysis suggests that some of
the effects observed in experimental animals
also occur in humans and that the body
burdens of dioxins associated with these
effects (adaptive and/or toxic) are similar
between animals and humans.
Methods
Comparisons ofanimal and human tissues
or cell lines studied under in vitro condi-
tions are shown in Table 1. This list is not
meant to be exhaustive. The data presented
are from peer-reviewed literature and
include only those papers that compared
animal and human tissues in the same
study or laboratory.
We estimated human body burdens
based on analyses ofdioxin in serum or tis-
sue in the cited literature. Several assump-
tions were used to derive body burdens
from these values. Dioxins are assumed to
be equally distributed in the bodylipid with
all tissues having the same concentration of
TCDD when expressed on a lipid-adjusted
basis (31-33). Thus, serum levels presented
as lipid-adjusted are assumed to be equiva-
lent to adipose tissue levels expressed as
lipid-adjusted values. In addition, we
assumed that for the average person, 22%
of the body weight is lipid or fat (34). To
estimate body burdens in humans, lipid-
adjusted serum or adipose tissue concentra-
tions (expressed as ng TCDD/kg or
TEQ/kg) were multiplied by 0.22 (34), the
fraction ofbodyweight that is fat.
Some of the body burden estimates in
humans presented here are based on tissue
concentrations of 2,3,7,8-tetrachlorodiben-
zo-p-dioxin alone. In all cases, humans were
likely to have been exposed to many dioxin-
like chemicals that bind to the Ah receptor
and produce the same spectrum of toxic
effects in experimental animals as TCDD
(2,14,26). To account for exposure to addi-
tional dioxins, the toxic equivalency factor
method (TEF) was used (14,35-38). TEFs
are relative potency factors used to convert
the amount of dioxins in a sample to
TCDD equivalents or TEQs (14,35-38).
TEFs were assigned only to 2,3,7,8-chlorine
substituted dibenzo-p-dioxins and dibenzo-
furans, the coplanar polychlorinated
biphenyl(s) (PCBs) (IUPAC nos. 77, 81,
126, and 169) and the mono-ortho-substi-
tuted PCBs (IUPAC nos. 105, 114, 118,
156, 157, 167, and 189). The TEF values
used for the dibenzo-p-dioxins and dibenzo-
furans were the U.S. EPA interim TEF val-
ues, which represent an internationally
accepted convention for assessment ofdiox-
ins (37,38). The TEF values used for the
dioxinlike PCBs were the World Health
Organization values, which resulted from a
recent international meeting of dioxin and
PCB experts (38). Hence, body burdens for
this complex mixture of related chemicals
are expressed in terms ofTEQs.
Body burden estimates in populations
exposed to background levels of dioxins
were based on published studies that mea-
sured serum concentrations of 2,3,7,8-
chlorine substituted dibenzo-p-dioxins
(CDDs) and dibenzofurans (CDFs) and
dioxinlike PCBs in populations with no
unusually high exposure to dioxins
(27-30,39). Serum concentrations of
CDDs and CDFs have been measured in a
number of different populations from sev-
eral studies. Schecter (27) presented data
indicating that the average whole-blood
CDD/CDF concentration in U.S. (n =
100) and German (n = 85) populations
were similar when presented on a TEQ
basis (41 and 42 ng TEQ/kg whole blood,
lipid adjusted). More extensive studies of
U.S. populations indicate that the national
average for serum CDD/CDF concentra-
tions is 28 ng TEQ/kg serum lipid (39).
Much smaller studies of congener-specific
PCB serum or adipose tissue concentra-
tions have been published that indicate
that average dioxinlike PCB concentrations
range from 8 to 17 ng TEQ/kg tissue lipid
in U.S. populations (28,30). The range of
average tissue TEQ concentrations for
CDDs/CDFs is 28-41 ng TEQ/kg lipid
and for the PCBs the range is 8-17 ng
TEQ/kg lipid. Based on these studies, aver-
age background dioxin tissue concentra-
tions range from 36-58 ng TEQ/kg lipid.
In these populations, TCDD contributes
approximately 15% ofthe total TEQ.
Body burden estimates in exposed pop-
ulations were based on the published litera-
ture. These populations were assumed to
have background exposures, in addition to
the specific exposures determined in the
study. The level ofdioxins in exposed pop-
ulations were often determined years after
the initial exposure. Body burdens were
estimated at the time of maximal exposure
assuming the rate oftotal body elimination
ofdioxins is linear with respect to time and
dose and a assuming 7.1-year half-life (40).
Determination ofmaximum body bur-
dens in experimental animals was based on
the administered dose and the rate ofelimi-
nation of dioxin from the animal. Total
body half-life of TCDD in experimental
animals was assumed to be first order with
respect to time and dose. In several cases,
body burdens in animals were based on tis-
sue levels determined in the study.
Effects seen in epidemiological studies
have been divided into two categories. The
first category (Table 2) is for effects that
have been causally associated with exposure
to dioxins. These are effects forwhich there
is strong evidence that the responses
observed are due to exposure to dioxins
and/or related compounds. Typically,
adverse effects with demonstrated causality
Table 1. Comparison ofthe effects ofTCDD exposure on human and animal tissue in vitro
Effect
TCDD binding to Ah receptor (Kd)
Induction of CYPlAl (EC50)
Cytotoxicity (LOEL)
Inhibition of proliferation (LOEL)
Inhibition of IgM secretion (LOEL)
Species/tissue Concentration (nM) Reference Appendix note8
Mouse (C57B1/6)
Human
Lymphocytes
Mouse
Human
Embryonic palate
Mouse
Rat
Human
Thymocytes
Mouse
Human
Lymphocytes
Mouse
Human
Lymphocytes
Mouse
Human
0.27
1.6
(42) a
(42) a
1.3
1.8
0.1
100
100
(46) b
(46) b
(47) c
(47) c
(47) c
0.1
0.1
(48) d
(49) d
3.0
0.3
3.0
0.3
(50)
(50)
(50)
(50)
e
e
e
e
LOEL, lowest observed effect level.
aThe data and methodology used to determine each value are presented in the appendix under the letter
indicated.
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Table 2 Responses in humans causally associated with exposure to dioxins and comparable effe
experimental animals
Effect Species
Chloracne Human
Monkey
Rabbit
Mouse
Experimental Body burden
dose (nglkg)
95-3,000
1,000ng/kg 1,000
4ng/rabbit, 23
5days/week/4weeks
4,000ng/kg, 13,900
3days/week/2weeks
Human (placenta)
Rat(liver) 125ng/kg/day,
30weeks
Mouse (liver) 10,000ng/kg
Induction of Human'
CYPlAl Rat(live
(maximal effect)
Inducton ofliver Rat
CYPlA1 (LOEL) Mouse
(placenta
,r)
Human
Rat
Human
Rat
Mouse
125ng/kg/day,
30weeks
1 ng/kg
1.5ng/kg/day,
5days/week/13weeks
TCDD
PCDD/PCDF
PCDD/PCDF/PCB
2,130
2,582
10,000
2,130
2,582
Api
n Reference
(51,52)
(53)
(54)
(55)
(18,56)
(57)
(58)
(18,56)
(59)
(60)
(61) 23
300
100
1.1
6-9
8-13
1
4
(62)
(62)
(67)
(61)
Abbreviations: EGFR, epidermal growth factor receptor; LOEL, lowest observed effect level; TCD
tetrachlorodibenzo-p-dioxin; PCDD, polychlorinated dibenzodioxin; PCDF, polychlorinated dibe
PCB, polychlorinated biphenyl.
"The data and methodology used to determine each value are presented in the appendix under
indicated.
are associated with high-level exposure and
are severe enough to dearly indicate a rela-
tionship with such exposure. Chloracne is
an example of such an adverse effect. In
addition, biochemical changes such as
induction of CYPlAI and decreases in
EGF receptor autophosphorylation are
included in this category because there is
significant experimental evidence that these
effects occur through activation of the Ah
receptor and are therefore causally related
to exposure to dioxinlike chemicals.
A second category (Table 3) was
assigned for effects associated with dioxin
exposure for which a causal link has not
been definitively proven. Effects included
in this category are decreased birth weight,
decreased growth, delayed developmental
milestones, cancer, decreased testosterone
levels, and increased risk of diabetes. In
both Tables 2 and 3, body burdens in
experimental animals are presented for
comparable toxic effects to those seen in
the epidemiological studies.
Table 4 presents body burdens in
experimental animals that produce an
effect for which no comparable human epi-
demiological data are yet available. The
current epidemiological database consists
primarily of studies on adult male popula-
tions; few studies ofwomen or children are
available. Only effects seen at low
body burdens in experimental anin
chosen for this table to estimate
end ofthe animal effect range; effi
as thymic atrophy, the wasting sy
or death are not included. The
assumptions and data used to der
value presented in Tables 1-4 are p
in the appendix.
Results
Comparisons of the in vitro ef
TCDD on animal and human ti
cell lines are shown in Table 1. A
ofinvestigations have found the A
tor present in humans to have a sir
slightly lower binding affinity for
than theAh ofmany other species
The concentration of TCDD req
produce equivalent effects in ani
human tissues is not significantly
for responses as varied as indu
CYPlAI in lymphocytes and th
proliferation (Table 1). For
responses, the effective concentr
TCDD differs in animal and hum
by an order of magnitude or
Cytotoxic effects induced by T
organ cultures ofdeveloping palate
concentrations 1000 times lower i
tissue than in either human or r
(48). Cultures ofembryonic human and rat
acts in palatal shelves respond at the same concen-
trations (48). Inhibition of lymphocyte
ipendix proliferation and secretion of IgM in
iotea mouse splenic lymphocytes requires 10
f times the concentration of TCDD com-
g pared to human tonsilar lymphocytes (50).
h Comparisons ofbody burdens associat-
ed with in vivo effects demonstrate similar
correlations between animals and humans.
Body burden estimates in individuals with
k chloracne vary by almost two orders of
magnitude (Table 2). In subjects with
chloracne, exposures resulted from either
industrial or accidental poisonings. In
k experimental animals, species differences
in body burdens of TCDD that induce
m chloracne vary by almost three orders of
n magnitude, with the rabbit the most sensi-
tive and the hairless mouse the least sensi-
0 tive. The range ofbody burdens that result
0 in chloracne in humans (96-3,000 ng
TEQ/kg body weight) and animals
p (23-13,900 ng TCDD/kg body weight)
p are similar. It should be noted that the first
q of these ranges represents interindividual
r variation while the second includes inter-
ID, 2,3,7,8- species variation.
Xnzofuran; Body burdens in the general population
were determined based on TCDD alone,
the letter total PCDDs/PCDFs, and total
PCDDs/PCDFs/PCBs (Table 2). The
average body burden ofTCDD in the gen-
doses or eral population is approximately 1.1 ng
ials were TCDD/kg body weight. The average body
the low burden in the general population for total
ects such PCDDs/PCDFs is 9 ng TEQ/kg body
ndrome, weight and for total PCDDs/PCDFs/PCBs
specific is 13 ngTEQ/kg bodyweight.
rive each Rice oil contaminated with PCDFs and
resented PCBs, among other contaminants, was
ingested by men and women from Taiwan
(Yu-Cheng incident); these individuals have
been carefully studied since the poisoning
ffects of incident (18,56,63-65). Biochemical
issues or changes in placentas from the women
.number exposed during the Yu-Cheng incident are
Lh recep- similar to the biochemical changes in rodent
nilar but liver from animals exposed to TCDD. Near
TCDD maximal downregulation of human placen-
(42-45). tal epidermal growth factor receptor
[uired to autophosphorylation occurs at similar body
imal and burdens, as do comparable decreases in
different hepatic epidermal growth factor receptor in
ction of rats and mice (Table 2). Maximal induction
ymocyte of hepatic cytochrome P-450 IAI
several (CYPlAI) in rats and mice by TCDD
ration of occurs at body burdens similar to those that
Lan tissue elicit maximal increases of CYPlAl in
greater. human placenta from the individuals
CDD in exposed during the Yu-Cheng incident. The
occur at lowest observable effect level (LOEL) for
in mouse enzyme induction in animals is 1 and 23 ng
rat tissue TCDD/kg body weight in rats (60) and
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Table3. Responses in humans associated with dioxin exposure and comparable effects in experimental
animals
Experimental Body burden Appendix
Effect Species dose (nglkg) Reference note8
Cancer Human 109-7,000 (19,23) s
Hamster 100pg/kg/month/ 137,000 (68) t
6months
Rat 100 ng/kg/day,2years 2,976 (69) u
Mouse 71 ng/kg/day,2years 944 (70) v
Tumorpromotion Rat(liver) 125ng/kg/day,30weeks 2,582 (71) k
Mouse(skin) 7.5ng/week,20weeks 830 (72) v
Decreased birthweight Human Maternal body burden 2,130 (18,56)
Rat 400ng/kg, maternal dose 400 (73) w
Hamster 2,000 ng/kg, 2,000 (8) w
matemal dose
Decreased growth Human Maternal bodyburden 2,130 (63)
Rat 1,000 ng/kg, 1,000 (75) w
maternal dose
Delayed developmental Human Matemal body burden 2,130 (64,65)
milestones
Objectlearning Monkey 0.151 ng/kg/day, 42ng/kg (66) x
Matemal bodyburden
Decreased testosterone Human 44-122 (41) y
Rat 12,500ng/kg 12,500 (76) u
Altered glucose Human 99-140 (24,25) z,aa
homeostasis Guinea pig 30ng/kg 30 (78) bb
Rat 100ng/kg/day,30days 2,000 (79) u
aThe data and methodology used to determine each value are presented in the appendix underthe letter
indicated.
Table 4. Low dose effects in animals exposed to dioxins
Experimental Body burden Appendix
Effect Species dose (ng/kg) Reference note8
Decreased offspring viability Rhesus monkey 0.76 ng/kg/day, 345 (80) x
4years
Rat 1,000 ng/kg 1,000 (74) w
Hamster 18,000 ng/kg 18,000 (81) w
Altered lymphocyte subsets Marmoset 0.3 ng/kg/week, 10 (82) cc
24weeks and
1.5 ng/kg/week,
12weeks
10 ng/kg 10 (83) cc
Enhanced viral susceptibility Mouse 10 ng/kg 10 (84) dd
Endometriosis Monkey 0.151 ng/kg/ 69 (85) x
day/4years
Decreased sperm count Rat 64 ng/kg, 64 (86) w
maternal dose
Testis abnormalities Rat 12,500 ng/kg 12,500 (76) u
Mouse 100 pg/kg 100,000 (77) ee
aThe data and methodology used to determine each value are presented in the appendix underthe letter
indicated.
mice (61), respectively, which is within the
range of background human body burdens
of13 ng TEQ/kg bodyweight.
Disposition of dioxins is dose depen-
dent in animals and humans (62). The
body burden necessary for hepatic seques-
tration is similar for rats and humans (624.
In animals, the body burden of TCDD
that produces a carcinogenic effect ranges
from 944 ng TCDD/kg body weight in
mice (70) to 137,000 ng TCDD/kg in
hamsters (68) (Table 3). Body burdens in
animals exposed to carcinogenic doses of
TCDD are 73- to 10,500-fold greater than
background human TEQbody burdens. In
epidemiological studies that indicate an
association between TCDD exposure and
increased incidence of cancer, body bur-
dens were estimated between 109 and
7,000 ng TCDD/kg at the time ofhighest
human exposure. Background human
TEQ body burdens are approximately
8-540 times less than human TEQ body
burdens estimated from the studies that
associated dioxin exposure with increased
cancer incidence.
Decreased birth weights were reported
in children born to women exposed during
the Yu-Cheng incident (18,56). These
women were highly exposed and had an
average body burden of approximately
2,130 ng TEQ/kg body weight. Body bur-
dens of dioxins in experimental animals
that decrease birth weight range from 400
to 2,000 ng TCDD/kg bodyweight in rats
and hamsters (73,74) (Table 3).
Children of the Yu-Cheng mothers are
not only smaller at birth but remain smaller
throughout childhood compared to chil-
dren of unexposed women (63). In rats,
pups of dams exposed to 1,000 ng
TCDD/kg body weight not only have
decreased birth weights but consistently
weigh less than controls up to 63 days of
age, though they do recover upon reaching
sexual maturity (75).
The Yu-Cheng children also exhibit
delayed developmental milestones (64,65).
Behavioral effects after perinatal TCDD
exposure have been observed in rhesus mon-
keys born to mothers exposed to approxi-
mately 5 ppt TCDD in the diet (66). Body
burdens in the rhesus mothers were 42 ng
TCDD/kg body weight, which is approxi-
mately 51 times less than the TEQ body
burden in the Yu-Cheng women, but only
3.2 times higher than average TEQ body
burden in thegeneral population.
Although some ofthe responses seen in
experimental animals appear to occur in
humans at similar body burdens, there are
significant differences in the body burden
estimates for decreased testosterone levels
(41) and between human and animals.
Based on these limited data, if decreased
testosterone in humans is due to dioxin
toxicity, then some humans may be
approximately 280 times more sensitive
than are rats for dioxin-induced decreases
in testosterone.
Increased incidence ofdiabetes in popu-
lations exposed to dioxins has been reported
in two studies with body burdens ranging
from 99 to 140 ngTEQ/kg. While TCDD-
induced diabetes has not been studied in
experimental animals, there are reports of
altered glucose homeostasis. Alterations in
glucose uptake in adipocytes isolated from
guinea pigs treated with TCDD occurs at
body burdens 3-4 times lower than human
populations with increased incidence ofdia-
betes and altered glucose tolerance (24,25).
Decreased serum glucose in rats occurs at
body burdens 14-20 times higher than the
increased incidence of diabetes and altered
glucose tolerance in humans.
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Table 4 presents estimated body bur-
dens of TCDD in experimental animals
from studies that report low-dose effects
for which no comparable human studies
are available. LOELs for decreased off-
springviability/fetal viabilityvary from 345
ng/kg in monkeys to 18,000 ng/kg in ham-
sters. Alterations in lymphocyte subsets in
juvenile marmosets is 10 ng TCDD/kg
body weight (82,83). Enhanced viral sus-
ceptibility, as measured by increased mor-
tality, occurs in mice at body burdens of
approximately 10 ng TCDD/kg (84),
which is equivalent to the body burden
seen in unexposed humans and approxi-
mately twice the level in untreated mice.
Effects such as increased incidence of
endometriosis in rhesus monkeys (85) and
decreased sperm count in offspring of rats
treated with TCDD (74,86) occur at body
burdens approximately five times that of
unexposed human populations.
Discussion
A number of investigators have found the
Ah receptor present in human tissues to
have a similar, but slightly lower, affinity
for TCDD than those receptors present in
many other species (42-45). For example,
a recent study determined that the appar-
ent binding affinity of TCDD to the Ah
receptor ranged from 0.4 to 15 nM in 115
human placentas and from 1 nM in the
TCDD responsive C57BI/6J mouse to 16
nM in the TCDD nonresponsive DBA/2
mouse. The binding affinity of TCDD to
the Ah receptor is similar in mice, rats,
hamsters, guinea pigs, and monkeys (87),
and there is no obvious correlation between
TCDD binding affinity to the Ah receptor
and species sensitivity to the lethal or toxic
effects of TCDD (87). Thus, our knowl-
edge of the quantitative relationship
between binding affinity and interspecies
responsiveness does not provide adequate
information to determine whether humans
are more or less responsive than other
species based solely on the binding affinity
ofTCDD to theAh receptor.
Comparisons of human tissues or cell
lines with similar animal tissues or cell lines
demonstrate that from relatively simple
responses, such as enzyme induction to
more complex phenomena, such as cyto-
toxicity and proliferation, human tissue
responds in the same manner as animal tis-
sue and at similar concentrations (Table 1).
These in vitro studies suggest that humans
will respond to dioxin and that some of
these responses may be adverse.
The doses of dioxins that produce
lethality in experimental animals can vary
by more than three orders of magnitude;
guinea pigs are the most sensitive and ham-
sters are the least sensitive (1-3). Because of
this large variability in lethal effects, there
has been an expectation that large species
differences exist for all other effects. The
data presented in the tables indicate that for
a particular effect, some species may be
extremely sensitive and some may be resis-
tant, but many species respond at similar
doses (i.e., within an order of magnitude).
All experimental mammalian species exam-
ined respond to most of the adverse effects
of dioxins at some dose. It is possible that
humans may be resistant to some of the
toxic effects of dioxins, but it seems highly
unlikely, given the data currently available,
that humans are refractory to all ofthe toxic
effects ofthese chemicals.
Dioxins are unequivocally potent toxi-
cants in experimental animals, yet the
human health effects of exposure to these
chemicals remain controversial. Compari-
sons of human and animal body burdens
alone cannot prove a cause-and-effect rela-
tionship between toxicity and exposure in
humans observed in an epidemiological
study. However, this information can be
used to increase or decrease our confidence
that a particular adverse health effect
observed in an epidemiological study was
associated with the exposure to dioxins.
In addition, the present analysis
required several assumptions in estimating
both animal and human body burdens.
These assumptions were required due to
the lack of complete data on pharmacoki-
netics, toxic equivalency factors, species
extrapolation, and, for humans, lack of
information on daily dose or exposures.
Hence, the information presented here can
be used to direct research efforts to provide
more accurate information on these topics.
There are some uncertainties associated
with the assumptions used to estimate
body burdens of dioxins in animals and
humans. Unlike the experimental animal
toxicology studies examined, humans are
exposed to multiple chemicals. However,
in the epidemiological studies, many of
these chemicals interact with the Ah recep-
tor as either agonists, partial agonists, or
possibly antagonists. Assumptions of the
relative potency of the chemicals and their
distribution in the humans will result in
uncertainties that are difficult to quantify
given the present database. However, these
uncertainties are likely well within an order
of magnitude because body burdens of
TCDD alone represent 10% of the total
TEQ body burden due to all the PCDDs,
PCDFs, and PCBs (Table 2).
Human body burdens are estimated
using the TEF methodology. The TEF val-
ues derived by the U.S. EPA and the
World Health Organization were based on
scientific judgment as well as experimental
data (37,38). In setting a TEF value, more
weight was given to long-term, in vivo
studies than to in vitro or acute in vivo
studies (14,36-38). In fact, although wide
ranges of TEF values have been reported
for specific congeners, the variability is
within a factor of 10 when the in vivo data
are used to set the TEF value (14,37,38).
The TEF methodology assumes addi-
tivity of toxic potential. The use of the
TEF methodology has been validated for
complex mixtures of chlorinated dibenzo-
p-dioxins for effects such as enzyme induc-
tion and tumor promotion (88). The inter-
action of mixtures containing both dioxin-
like and non-dioxinlike chemicals has not
been studied as thoroughly. There are
reports of antagonistic (89-91) and syner-
gistic (92,93) interactions of dioxins and
non-dioxinlike PCBs. The demonstration
of nonadditive interactions increases the
uncertainty of these values. Finally, the
TEF scheme includes only full agonists of
the Ah receptor. The use ofTEFs and the
assumption of additivity have been
approved by both the World Health
Organization and the U.S. EPA as a
default, but interim, approach given the
enormity ofthe task to test for all possible
interactions ofcomplex mixtures and in the
relative absence of consistent data to the
contrary (94). Clearly, the TEF values and
assumptions regarding additivity need to be
updated as more data become available.
Estimates of body burdens in animals
and humans assume that the half-life of
elimination of dioxins is a first-order
process which is independent of the body
burden or dose. There is significant evi-
dence that disposition of TCDD is dose
dependent (95-97). Induction ofa binding
protein in the liver has been proposed by
Andersen et al. (98) to explain the dose-
dependent disposition of TCDD seen in
experimental animals. Similar dose-depen-
dent hepatic sequestration has been pro-
posed in humans (62). These data suggest
that elimination of these chemicals may
not be a first-order process and the use ofa
single one-component half-life to estimate
body burdens may not adequately predict
these values.
Two different methods were used to
estimate body burdens in experimental ani-
mals. One method involved classical phar-
macokinetic calculations, and the second
method used tissue concentration data pre-
sented in the papers. These methods result-
ed in similar body burden estimates for
some cases where the appropriate data were
available. For example, in mice receiving
1.5 ng TCDD/kg/day, estimated body
burdens using classical pharmacokinetic
Volume 103, Number9, September 1995 * EnvironmentalHealth Perspectives 824Reviews * Body burdens of dioxins in humans and animals
calculations were 14 ng TCDD/kg body
weight and 23 ng TCDD/kg body weight
using TCDD tissue concentrations. Body
burden estimates from a tumor promotion
study with rats receiving 125 ng TCDD/
kg/day produces estimates of 3615 ng
TCDD/kg body weight using pharmacoki-
netic calculations and 2582 ng TCDD/kg
body weight using TCDD tissue concen-
trations. These results suggest that the use
of either method to derive body burdens
will result in reasonably accurate estimates.
In estimating human body burdens, we
assumed that dioxins distribute solely to the
lipid portion ofthe body and that the con-
centration ofdioxins in serum lipid is direct-
ly correlated to the concentration ofdioxins
in total body lipid. Several studies have
demonstrated direct correlation between
lipid-adjusted serum and adipose tissue con-
centrations of dioxins from human biopsy
samples for the lower chlorinated dibenzo-p-
dioxins and dibenzofurans (30-33). This
relationship is not as certain for the higher
(six or more chlorine substitutions) chlori-
nated analogs. Furthermore, in humans
exposed to background levels ofdioxins, the
absolute or lipid-adjusted concentrations of
CDDs and CDFs in adipose tissue and liver
are not directly related and liver/fat ratios
vary between 1.22 and 15.42 depending on
the congener and possibly on dose (99). The
highly chlorinated dibenzo-p-dioxins and
dibenzofurans are found in greater concen-
tration in the liver compared to the fat
(liver/fat ratio 7.4-15.42). In the same sam-
ples, TCDD had a liver/fat ratio ofapproxi-
mately 2 (96). The human liver appears to
accumulate these chemicals in greater pro-
portion than adipose tissue, similar to what
has been observed in experimental animals.
In experimental animals, liver/fat concentra-
tion ratios are notonlydifferent fordifferent
compounds, but they are dose dependent.
As the dose ofdioxins are increased, so is the
liver/fat ratio (95-98).
Using the assumption that dioxins are
equally distributed in the body lipid may
underestimate the body burden of these
chemicals due to chemical and dose-depen-
dent sequestration in the liver. The magni-
tude ofunderestimation can be determined
if several assumptions are used: that the
liver/fat ratio for all dioxins is 15 and that
liver is 10% ofthe bodyweight and is 10%
lipid by weight. A liver/fat ratio of 15, as
determined for the hexachlorodibenzofu-
rans in humans, is used as a worst-case sce-
nario for hepatic sequestration. Using these
assumptions, the present estimate ofdioxin
TEQbody burdens in background popula-
tions will change from 13 to 21 ng
TEQ/kg body weight. Hence, the assump-
tion that dioxins are equally distributed in
body lipid may slightly underestimate the
body burdens of these chemicals, but the
magnitude oferror will be less than a factor
oftwo. A better understanding ofthe phar-
macokinetic properties for this class of
compounds in humans is dearly indicated.
Chloracne has been described as the hall-
mark of dioxin toxicity in humans (17).
Dioxin exposure in several animal species
results in a chloracnegenic response and the
body burdens which produce this response
in animals are similar to the bodyburdens of
dioxins in humans with chloracne. The
chloracnegenic response has been thought to
be a relatively high-dose phenomenon; how-
ever, thevariation in human sensitivityto the
chloracnegenic effects ofTCDD is almost
two orders ofmagnitude. For example, there
are individuals who developed chloracne at
body burdens approximately three times
background (51). In contrast, there are sub-
jects with bodyburdens of1450 ngTEQ/kg
body weight who have not developed chlo-
racne (51). These data suggest that humans
differ widely in sensitivity to the chloracne-
genicactions ofdioxins.
There are two points of caution when
interpreting the chloracne data. First,
human body burdens may not be an accu-
rate measure of chloracnegenic potential if
point-of-contact concentrations are impor-
tant. For example, ifdermal exposure results
in a localized chloracnegenic response, body
burdens estimated from serum or adipose
tissue levels may not accurately reflect the
concentration ofdioxins at the site ofeffect.
Also, the lackofchloracne in highlyexposed
patients does not necessarily indicate that
these individuals are resistant to all the
effects ofdioxins. In mice, gene products, in
addition to the Ah receptor, regulate the
chloracnegenic response (100). It seems like-
ly that multiple genetic factors may influ-
ence the relative susceptibility ofindividuals
in aresponse-specific fashion.
Human responses to dioxins other than
chloracne are not as obvious. In the Yu-
Cheng poisoning incident, increased rates
of toxic effects such as miscarriages, still-
births, low birth weight infants, and devel-
opmental delays have been observed in off-
spring ofwomen exposed to high levels of
PCDFs and PCBs. However, it has been
difficult to determine if the effects are due
to the dioxins in the mixture, the non-
dioxinlike PCBs, or to the combination of
these chemicals. Researchers have tried to
correlate effects with serum concentrations
of either the PCDFs or PCBs (56). Birth
weights were negatively correlated with
PCDF levels in these individuals (56).
Other effects such as induction of arylhy-
drocarbon hydroxylase activity, a marker
for CYPlAI, were not correlated with
either the polychlorinated dibenzofurans or
the PCB concentrations, but decreased pla-
cental EGF receptor autophosphorylation
was correlated with total PCB concentra-
tions (56). However, due to the nature of
the exposure, patients with high levels of
dibenzofurans will likely have high levels of
PCBs, making such correlations difficult to
interpret. Also, the presence of dioxinlike
and non-dioxinlike PCBs adds to the com-
plexity ofthese correlations.
We compared the body burdens of
dioxins in the Yu-Cheng population to
body burdens in experimental animals to
determine the role of dioxins in the toxic
effects seen in these individuals. Women
who were pregnant at the time ofexposure
or became pregnant thereafter had children
with lower birth weights compared to unex-
posed women, and the decrease in size per-
sisted years after birth (63). Body burdens
in the Yu-Cheng mothers were estimated at
2130 ng TEQ/kg. In experimental animals
the body burdens that result in decreased
birth weights range from 400 to 2000 ng
TCDD/kg, while decreased growth occurs
in rats at 1,000 ngTCDD/kg. The similari-
ties between the body burdens in animals
and humans suggests that dioxins may play
a role in the decreased birthweights.
The behavioral effects of dioxins have
not been thoroughly studied in experimen-
tal animals. One study reported deficien-
cies in object learning in rhesus monkeys
prenatally exposed to TCDD. Delayed
developmental milestones were seen in
children born to Yu-Cheng mothers, but
the body burdens are approximately 51
times higher in humans than in the mon-
keys. There is recent evidence that some of
the non-dioxinlike PCBs may have neuro-
toxic actions (101). The absence ofstudies
in experimental animals examining the
developmental behavioral toxicity of diox-
ins makes it difficult to assess the role of
either the dioxins or the non-dioxinlike
PCBs in the developmental effects of the
children oftheYu-Cheng patients.
In experimental animals, some bio-
chemical changes produced by dioxins
occur at lower body burdens than do the
toxic effects (57-61,71). Induction of
CYPlAl and decreased hepatic EGF recep-
tor are two well-characterized biochemical
responses to TCDD. Earlier studies com-
paring the induction of CYPlAl and
decreased EGF receptor in human placenta
and rat liver suggested that humans may be
more sensitive when compared on a tissue-
dose basis (18). However, it is possible that
the difference in sensitivity is not entirely
due to species differences but due to altered
tissue sensitivity. For example, induction of
GCYPlA1 is similar in lung, liver, and skin
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of mice based on administered dose (102).
In contrast, when the sensitivity of these
tissues is compared on a tissue-dose basis,
the lung is much more sensitive than the
liver or skin (102). The present study indi-
cates that humans and rats are equally sen-
sitive to TCDD-induced biochemical
changes when compared on a total body
burden. Thus, when comparing the relative
sensitivity of human or animal tissues to
TCDD-induced biochemical changes, it
may be more appropriate to compare body
burdens than tissue concentrations. In
addition, these data provide support for
our approach.
TCDD is clearly carcinogenic in exper-
imental animals. All species and both sexes
of experimental animals that have been
chronically exposed to TCDD exhibit a
dose-dependent increased incidence of
tumors (5). Several recent epidemiological
studies have indicated an association
between TCDD serum concentrations and
increased incidence of tumors (19-23).
Body burdens in rats and mice with
increased tumors are comparable to the
body burdens in the human cohorts that
have increased incidence oftumors thought
to be associated with dioxin exposure.
Although these data are not conclusive,
they are consistent with the hypothesis that
exposure to TCDD was an important fac-
tor in the increased incidence oftumors in
these cohorts. It is interesting to note that
based on body burdens, mice are more sen-
sitive to the carcinogenic effects ofTCDD
than are rats.
Carcinogenic responses are seen in
hamsters, but the carcinogenic doses pro-
duce body burdens 46-1,300 times that
seen either in humans, rats, or mice.
Hamsters are insensitive to the lethal effects
ofdioxins, and they may also be less sensi-
tive to the carcinogenic response. However,
responses such as cancer are dose depen-
dent as well as time dependent. Thus, the
apparent differential sensitivity ofthe ham-
ster may be due to differences in the
dose-time regimens used in the hamster
compared to the rat and mouse studies. It
would be useful to compare these species
under similar exposure protocols.
Decreases in serum testosterone have
been reported in a National Institute of
Occupational Safety and Health (NIOSH)
cohort (41). There was a decrease in testos-
terone concentrations in individuals with
serum concentrations of TCDD as low as
20 ppt at the time oftissue sampling, which
is 3-4 times background TCDD levels and
only a 33% increase over total average body
burdens. Although the decrease in testos-
terone concentrations was statistically signif-
icant, the decrease was minor, and average
levels were still within the normal range. In
addition, a clear association between serum
TCDD concentrations and effect was not
readily apparent in the data (41). If differ-
ences in exposure patterns in the individuals
are taken into account by back-calculating
serum TCDD concentrations to the time of
exposure, there is a clearer association
between serum TCDD concentrations and
lower testosterone concentrations. Here the
lowest serum TCDD concentration associ-
ated with decreased testosterone concentra-
tion is 140 ppt (200 ppt TEQ). In experi-
mental animals, high doses of TCDD
decrease testosterone concentrations in rats
at a body burden of 12,500 ng TCDD/kg
body weight (73). These data suggest that
some humans may be approximately 280
times more sensitive to the testosterone-
decreasing effects of dioxins compared to
rats. Alternatively, the decreased testosterone
levels in the NIOSH cohort could be related
to the concomitant exposure to other chem-
icals involved in the manufacturing process.
Future studies examining the sensitivity of
other species to the testosterone-decreasing
effects of dioxins and epidemiological stud-
ies of other populations may provide addi-
tional information to adequately assess the
association between dioxin exposure and
decreased testosterone concentrations in
some human populations.
Many of the effects of TCDD have
been studied following an acute exposure
in experimental animals. In contrast,
humans receive low daily doses of these
chemicals. One of the assumptions in
extrapolating these effects to humans is
that the effects are solely related to body
burdens. For some ofthese endpoints, such
as decreased testosterone, this assumption
has not been adequately tested. Effects such
as cancer are clearly related to both dose
and time. It is possible that, in addition to
dose and body burden, length of exposure
may also have a significant effect on toxici-
ty. Analysis ofthe area under the total body
concentration-time curve may be a more
appropriate marker for dose, and analysis
ofthese data sets is ongoing.
The clinical significance ofsome ofthe
endpoints studied is uncertain. Induction
of CYPlAI and CYP1A2 by TCDD are
some ofthe most sensitive markers ofdiox-
in exposure, yet their relevance to toxicity
is unclear. Recent studies have suggested an
association between PAH exposure and
CYPlA1/lA2 induction for lung and col-
orectal cancer and athelerosclerosis
(103-105). However, these associations are
speculative and not proven. At present, one
could conclude that low doses of dioxins
produce effects such as enzyme induction
in experimental animals and that humans
are exposed to levels ofdioxins that induce
CYPlA1/lA2 in experimental animals, but
the relationship between these effects and
disease are uncertain.
One of the most sensitive targets for
TCDD toxicity in experimental animals is
the immune system. Immune alterations,
including increased viral sensitivity in mice
and altered lymphocyte subsets in mar-
mosets, have been reported at body bur-
dens equivalent to human background
exposures. However, the evidence for
immunotoxicity of dioxins in humans is
inconclusive. There are reports of subtle
immune alterations in populations heavily
exposed to dioxins. The incidence of
intestinal and upper respiratory tract infec-
tions correlated with chloracne state and
increased with increasing serum TCDD
concentrations (106). One year after the
Yu-Cheng poisoning episode, patients
exhibited decreases in percentage of total
T-cells, active T-cells, and T-helper cells,
which recovered by the 3-year follow up
study (107). Recent studies ofoccupation-
ally exposed individuals with slightly ele-
vated bodyburdens ofapproximately 72 ng
TEQ/kg showed no alterations in lympho-
cyte subsets (108). However, in mice, a
dose of TCDD that suppresses the anti-
body response to sheep red blood cells is
not associated with alterations in lympho-
cyte subsets (109). Thus, immune function
maybe alteredwithout altering lymphocyte
subsets. Although some of these data sug-
gest that the human immune system may
be sensitive to the effects of dioxins, our
present understanding ofimmunology does
not support a conclusion that these alter-
ations are or are not clinicallysignificant.
The present study indicates that in
vitro similar responses are seen in human
and animal tissues after similar dioxin
exposure. Human populations exposed to
high concentrations of dioxins exhibit
symptoms that are similar to the signs of
toxicity seen in some experimental animals
exposed to dioxins. These effects are seen at
equivalent body burdens, strongly indicat-
ing that dioxins are responsible for some of
these toxic effects in humans. For most of
the toxic effects of dioxins, background
exposure is well below those associated
with overt toxicities. However, the back-
ground level used in this evaluation (13 ng
TEQ/kg body weight) is an average back-
ground. Body burdens ofdioxins appear to
be log-normally distributed in humans
(110), thus it would not be unusual to see
populations with body burdens three to
four standard deviations beyond the mean
body burden. Recent studies in the
Netherlands indicate that plasma TEQ
concentrations in the 95th percentile ofthe
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population are twice that of the mean
(113), suggesting that at least 5% of the
population has two times the mean body
burden. In addition, there are subpopula-
tions such as subsistence fishermen who are
likely to have much greater body burdens.
There are also some toxic effects, such as
endometriosis and increased viral sensitivi-
ty, which occur in experimental animals at
body burdens less than 10 times the aver-
age background exposures to humans.
Finally, human exposures that result in
adverse health effects, such as chloracne,
decreased birth weights, developmental
delays, and cancer are 3-540 times the pre-
sent average background exposure to these
chemicals. Nevertheless, the available data
indicate that high-level human exposure to
dioxins produce adverse health effects and
that humans are a sensitive species to the
toxic effects ofdioxins. Whether these low-
dose effects are occurring in the general
population or the more highly exposed
subpopulations remains to be determined.
Appendix. Table Notes
(Some notes appear in more than one
table.)
Table 1
a) Apparent equilibrium binding dissocia-
tion constants are presented (42). Under
conditions ofinfinite dilution, an appar-
ent Kdof9 pM has been determined for
the Al) allele in the C57BI/6 mice; this
value is close to the estimated true Kd
(43).
b) Splenic lymphocytes from C57BI/6
mice and peripheral blood lymphocytes
were isolated, cultured, and exposed to
TCDD. Ethoxyresorufin-O-deethylase
(EROD) activity, a marker for CYPlAl,
was determined following TCDD expo-
sure (43).
c) The authors (47) compared the cytotox-
ic effects ofTCDD on organ culture of
human, mouse and rat embryonic
palatal shelves. Embryonic palates from
human, mouse and rat were grown in
the same organ culture system and
exposed to TCDD. Cytotoxicity was
detected using transmission electron
microscopy.
d) Thymocytes were isolated from either
murine or human sources and cocul-
tured with either murine (48) or human
(49) thymic epithelium culture. The
incorporation oftritiated thymidine into
DNA was determined in cells treated
with TCDD following antigen stimula-
tion.
e) Human tonsilar lymphocytes and
murine splenic lymphocytes were used
as a source of B-cells. Human and
murine B-cells were grown under identi-
cal conditions and exposed to TCDD.
Proliferation and IgM secretion were
determined in response to different con-
centrations ofTCDD ranging from 0.3
to 30 nM (50).
Table 2
f) The lower value, 96 ng TEQ/kg body
weight, is the body burden estimate ofa
patient with the lowest reported adipose
dioxin concentration for any patient
with chloracne (51). This individual was
exposed to a mixture of CDDs and
CDFs in 1969 and developed chloracne.
At the time of exposure this individual
had adipose tissue CDD/CDF concen-
trations of419 ng TEQ/kg adipose tis-
sue (51). An additional 17 ng TEQwas
added to this value to include the PCBs.
The values of dioxins at the time of
exposure were estimated by the authors
(51). The higher ofthe two values repre-
sents the average body burden ofdioxins
(TEQs) in individuals from Yusho with
chloracne (52). Estimates of body bur-
dens from these individuals were deter-
mined byRyan et al. (52).
g) Rhesus monkeys were administered 1
pig/kg TCDD, and it is assumed that
essentially no TCDD was eliminated
when the animal developed a chloracne-
genic response. This is a LOEL dose; no
lower doses were tested (53).
h) Assumes the rabbit and the rat have the
same rate of elimination, a half-life of
23.7 days (88) and that the rabbits
weighed 2.5 kg throughout the experi-
ment. This is a LOEL dose; no lower
doses were tested (52).
i) Assumes the half-life ofTCDD in mice
is 11 days and that the mice weigh 25 g.
This is a LOEL dose; no lower doses
wereadministered (5).
j) In highly exposed patients from the Yu-
Cheng incident, there is a decrease in
birth weights of children born from
these patients compared to unexposed
control populations (18,56). In addi-
tion, theYu-Chengmothers have altered
levels ofplacental epidermal growth fac-
tor receptor (EGFR) and CYPlAI. The
data indicate that the changes in placen-
tal EGFR and CYPlAl in these patients
were maximal. Body burdens deter-
mined based on levels of2,3,4,7,8-pen-
tachloro-dibenzofuran (TEF = 0.5) and
1,2,3,4,7,8-hexachlorodibenzofuran
(TEF = 0.1) in placenta tissue. Lipid
content of the placenta is estimated at
1% (112) and the average percent body
fat of a women is assumed to be 22%.
These body burden estimates were also
used as body burdens of Yu-Cheng
mothers whose children demonstrate
decreased growth (63) and delayed
developmental milestones (64,65).
k) In a rat liver tumor promotion study,
rats initiated with diethylnitrosamine
were exposed to doses of TCDD from
3.5 to 125 ng/kg/day. Statisticallysignif-
icant increases in numbers of altered
hepatic foci were observed in rats treated
with 125 ng TCDD/kg/day (62). At the
end ofthe study, liver concentrations of
TCDD were approximately 20 ppb
(60); assumes 20% body weight is adi-
pose tissue and that at this dose, the liver
has three times the concentration of
TCDD than adipose tissue. Body and
liver weights were reported (67) for
these animals. The body burden calcula-
tion assumes that liver and fat account
for 85% of the body burden in these
animals. For tumor promotion, 125 ng
TCDD/kg/day is the LOEL and 35 ng
TCDD/kg/day is the NOEL for tumor
promotion (67). For induction of
CYPlAl (60) and downregulation of
EGFR (59), 125 ng TCDD/kg/day was
assumed to produce amaximal response.
1) Mice were administered 10 pg TCDD/
kg and sacrificed 7 days after treatment.
EGFR binding was determined in
hepaticplasmamembrane (58).
m)Animals received a single dose and were
sacrificed 24 hr later. Assumes no
TCDD eliminated at this time.
CYPllAl induction determined by RT-
polymerase chain reaction (60). The
LOEL for CYPlAI induction was 1
ng/kg, a no observed effect level from
this studyis 0.1 ng/kg.
n) Animals received 1.5 ng/kg/day 5
day/week for 13 weeks (61). Mice were
sacrificed 3 days after last dose. Hepatic,
dermal, and pulmonary EROD activity
were significantly induced at this dose.
Tissue concentrations of TCDD were
measured in liver, skin, and fat. Body
burden estimates assumes 95% of the
body burden is in liver, skin, and fat.
This is the LOEL from this study; no
lowerdoses were tested.
o) Body burdens are estimated by authors
(62) for the increased accumulation of
PCDD/PCDF in liver compared to adi-
pose tissue using a pharmacokinetic
model.
p) Assumes average level of dioxins and
dibenzofurans in human serum ranges
from 28 to 41 TEQ ppt and from 8 to
17 TEQ ppt for the PCBs. Thus, the
average TEQranges from 36 to 58 TEQ
ppt. Using 58 ppt as the average concen-
tration of PCDDs, PCDFs, and PCBs
in serum, a body burden of 12.76 ng
TEQ/kg body weight was calculated.
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For PCDD and PCDF concentrations, a
body burden of 9 ng TEQ was deter-
mined. Average concentrations of
TCDD in adipose tissue are 5 ppt (lipid
adjusted) (27), resulting in a body bur-
den of1.1 ngTCDD/kg.
q) In control rats, PCDDs and PCDFs
were determined at different ages; 200-
day-old rats had approximately 78 ppt
TEQs in liver (67. This is an equivalent
liver concentration in 60-day-old rats 24
hr after administration of 1 ng
TCDD/kg.
r) Liver, fat, blood, and skin concentra-
tions of TCDD, 1,2,3,7,8-PCDD,
2,3,7,8-TCDF, 1,2,3,7,8-PCDF,
2,3,4,7,8-PCDF, and OCDF were
determined in 150-day-old female
B6C3F1 mice. The TEF methodology
was used to estimate TEQlevels in these
animals; assumes that 95% of the body
burden is in liver, fat, and skin.
Table 3
s) Estimated highest body burden at time
of last exposure. Calculations based on
measured TCDD levels in serum (lipid
adjusted) and assuming a first-order
elimination kinetics and a half-life for
elimination of7.1 years. Also assumes a
bodyweight of70 kg and 22% body fat.
Calculations for estimated serum con-
centrations at last time ofexposure per-
formed byauthors (18,23).
t) Animals administered 100 pg
TCDD/kg 6 times every 4 weeks over a
24-week period; assumes a half-life of
14.9 days (111). Body burdens are esti-
mated immediately after the last treat-
ment with TCDD. The administration
of 50 pg TCDD/kg 6 times every 4
weeks over a 24-week period did not
increase the incidence of any types of
tumors in 10 hamsters (68).
u) Assumes a single first-order elimination
rate constant and a half-life for the
whole body elimination of 23.7 days
(85) and a gastrointestinal tract absorp-
tion of86% (85). Increased incidence of
hepatocellular carcinomas were observed
at 100 ng/kg/day and 10 ng/kg/day is
the NOEL (69). Decreased testis weight
and testosterone concentrations were
observed after 12.5 ngTCDD/kg 7 days
later (76). Decreased serum glucose lev-
els were observed in rats treated with
100 ng/kg/dayfor 30 days (79).
v) Assumes an apparent half-life of 11 days
and a bodyweight of20 g. Mice receiv-
ing 71.4 ng/kg/day for 2 years had a sta-
tistically significant increase in hepato-
cellular carcinomas (7().
w) Assumes neonatal rats and hamsters are
exposed to an equal dose of TCDD as
are the dams on a weight basis and
assumes all alterations are due to the
neonatal exposure. For decreased body
weight in pups 400 ng/kg is the LOEL;
a dose of 64 ng/kg to the dam was the
NOEL for this response (73). For
decreased sperm count the LOEL is 64
ng/kg and no lower doses were tested
(86). In hamsters onlyone dose was test-
ed (2000 ng/kg) for decreased sperm
counts (74). Decreased growth in rats is
indicated by decreased body weights up
to postnatal day 63 (75). The incidence
offetal mortality was increased in ham-
sters at a dose of 18 pg/kg but not at a
dose of6 pg/kg (81).
x) Assumes a single first-order elimination
rate constant and a half-life for the
whole-body elimination of 400 days
(81) and a gastrointestinal absorption of
86% (88). This is the LOEL from this
study; no lower doses tested. Monkeys
exposed to a diet ofapproximately 5 ppt
had a daily intake of 0.151 ng/kg/day.
Monkeys exposed to approximately 25
ppt in the diet had a daily intake of
approximately 0.76 ng/kg/day. For ani-
mals with decreased object learning, the
TCDD-exposed offspring were born
after 16.2 months of maternal TCDD
exposure of a diet of 0.151 ng TCDD/
kg/day. Animals with increased inci-
dence and severity ofendometriosis had
a daily intake of 0.151 ng/kg/day for 4
years, and body burdens were deter-
mined at the end ofthe exposure period.
Monkeys exposed to 0.76 ng TCDD/
kg/day for 16.2 months had significant
decreases in offspringviability.
y) The authors extrapolated serum concen-
trations of TCDD at the time of sam-
pling to initial exposures (41). Workers
with serum TCDD concentrations of
140-496 ng/kg (lipid adjusted) have a
greater incidence of low testosterone
concentrations (41). Extrapolation
assumed a half-life for TCDD of 7.1
years. To estimate body burdens in these
workers, it was assumed that the back-
ground TEQ was 60 ng/kg, thus the
total serum TEQwas 140 ngTCDD/kg
+ 60 ng TEQ/kg = 200 ng TEQ/kg
(lipid adjusted).
z) Assumes that high-exposed group (>33
ng/kg) had a background of 60 TEQ
ng/kg. This group had at least 93 TEQ
ng/kg. Assumes average subject was
male, weighing 70 kg with 22% body
fat.
aa)Workers with increased glucose toler-
ance and diabetes have serum levels of
640 pptTEQ(24).
bb) Guinea pigs received 30 ng TCDD/kg
intraperitoneally and sacrificed 24 hr
after dose. Assumes that no TCDD
was eliminated at this time. This is a
LOEL, no other doses tested (78).
Table 4
cc) Assuming a single first-order elimina-
tion rate constant and a half-life of6-8
weeks. Body burdens calculated by
authors (82). Animals treated with a
single dose of TCDD were tested 2
weeks aftertreatment (83).
dd) Mice were treated with TCDD and
challenged with influenza virus 7 days
later (84).
ee) Micewere administered 100 rig/kg and
examined 30 days after receiving the
treatment (77).
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Society of Toxicology
Reproductive and Developmental Toxicology Subsection
Graduate/Postdoctoral Student Award
We announce our intention to make awards of recognition for the best platform and/or poster presen-
tation by graduate students or postdoctoral fellows in the areas of reproductive and developmental toxi-
cology at the 1996 Annual Meeting of the Society of Toxicology, which will be held in Anaheim, California on
March 10-14. General areas of research can include female or male reproductive toxicology, reproductive
endocrine toxicology, teratologyldevelopmental toxicology, and/or postnatal functional assessment.
Candidates for these awards should send to the address listed below, by November 1, 1995, a copy of the
abstract that is being submitted to the Society for this meeting. An outline of the talk or a copy of the
poster material should also be included if possible, to assist thejudges.
The abstracts and posters should describe original research which may include applied studies, inves-
tigations of mechanisms of toxic response, or studies of basicL biochemical, physiologic, or genetic mecha-
nisms of action. Interested individuals may request Society information and abstract forms from the
address below. All submitted material will be treated as confidential. The winning presentations will be
announced at the Annual Meeting of the Specialty Subsection in Anaheim. For further information, please
contact:
Robert J. Kavlock, Ph.D.
U.5. Environmental Protection Agency
Health Effecto Research Laboratory
Developmental Toxicology Pivision (MD-71)
Research Triangle Park, NC 27711
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